1. |
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes[J]. N Engl J Med, 2004; 351(19): 1941-1951.
|
2. |
Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial[J]. Ann Intern Med, 1998; 128(12 Pt 1): 982-988.
|
3. |
Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure[J]. Hypertens Res, 2003; 26(6): 453-458.
|
4. |
Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy[J] ? J Am Soc Nephrol, 2001; 12(3): 602-605.
|
5. |
O’Hare P, Bilbous R, Mitchell T, O’Callaghan CJ, Viberti GC; Ace-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial[J]. Diabetes Care, 2000; 23(12): 1823-1829.
|
6. |
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients[J]. Diabetes Care, 2000; 23(Suppl 2): B21-29.
|
7. |
Arcaro G, Zenere BM, Saggiani F, et al. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria[J]. Diabetes Care, 1999; 22(9): 1536-1542.
|